



Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 41380

Manuscript Type: ORIGINAL ARTICLE

Observational Study

Loss of ¹⁸efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease

María Fernanda Guerra Veloz, Federico Argüelles-Arias, ¹⁵Luisa Castro Laria, Belén Maldonado Pérez, Antonio Benítez Roldan, Raúl Perea Amarillo, Vicente Merino Bohórquez, Miguel Angel Calleja, Ángel Caunedo Álvarez, Ángel Vilches Arenas

Match Overview

1	Internet 114 words crawled on 17-Apr-2018 link.springer.com	2%
2	Crossref 61 words Stefanos Bonovas, Laurent Peyrin-Biroulet, Silvio Danese. "Infliximab biosimilar CT-P13 for inflammatory bowel ..."	1%
3	Crossref 55 words K K Jørgensen, G L Goll, J Sexton, I C Olsen et al. "P483 Long-term efficacy and safety of biosimilar infliximab (CT"	1%
4	Crossref 54 words E Flanagan, E Wright, J Begun, R Bryant, D Sathananthan, S Bell. "P520 Gastrointestinal ultrasonography in preg"	1%
5	Internet 48 words crawled on 30-Sep-2018 eprints.whiterose.ac.uk	1%
6	Internet 48 words crawled on 28-Dec-2017 www.dovepress.com	1%
7	Crossref 48 words Y. Komaki, A. Yamada, F. Komaki, D. Micic, A. Ido, A. Sak	1%



找到约 14,200 条结果 (用时 0.65 秒)

P519 Switching from reference infliximab to CT-P13 in patients with ...

<https://www.ecco-ibd.eu/.../p519-switching-from-reference-infliximab-to-ct-...> [翻译此页](#)

Infliximab have changed the natural history of **inflammatory bowel diseases (IBD)**. However, with the advent of **biosimilar** treatment such as **CT-P13** promises to improve ... Here, we assess the **effectiveness** and **safety** of **switching** to **CT-P13** from **infliximab** reference product (RP) ... **Loss of efficacy** at 12 months was 15.7%.

缺少字词: original

Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926778/> [翻译此页](#)

作者: R Keil - 2016 - [被引用次数: 33](#) - [相关文章](#)

2016年3月22日 - This article has been cited by other articles in PMC. Go to: The **effectiveness** of **infliximab** RMP in **patients** with **IBD** has been ... **IBD** affects nutritional status in **patients** and **weight loss** is a fundamental symptom of the disease. (PKs), **efficacy** and **safety** of **CT-P13** and **original infliximab** RMP, with these ...

Switching from reference infliximab to CT-P13 in patients with ... - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed/29893581> - [翻译此页](#)

作者: VMF Guerra - 2018

2018年6月12日 - **Switching** from reference **infliximab** to **CT-P13** in **patients** with ... changed the natural history of **inflammatory bowel disease (IBD)**. The advent of **biosimilar** treatments such as **CT-P13** will hopefully ... The objective of the study was to assess the **effectiveness** and **safety** of **switching** from the reference product ...

缺少字词: original

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in ...

找到约 14,700 条结果 (用时 0.61 秒)

P519 Switching from reference infliximab to CT-P13 in ... - ECCO IBD

<https://www.ecco-ibd.eu/.../p519-switching-from-reference-infliximab-to-ct-...>  翻译此页

However, with the advent of **biosimilar** treatment such as **CT-P13** promises to ... Here, we assess the **effectiveness** and **safety** of **switching** to **CT-P13** from **infliximab** reference product (RP) in **patients** with **IBD**. ... All **patients** were **switched** from **infliximab** RP (**Remicade**[®]) to **CT-P13** ... **Loss** of **efficacy** at 12 months was 15.7%.

缺少字词 : original

Switching from reference infliximab to CT-P13 in patients wi ...

https://journals.lww.com/.../Switching_from_reference_infliximab_to_CT_P...  翻译此页

作者 : F Argüelles-Arias - 2017 - 被引用次数 : 15 - 相关文章

Original Articles: Inflammatory Bowel Disease ... Conclusion **Switching** from **infliximab** RP to **CT-P13** is **efficacious** and well tolerated in ... In **patients** with **IBD**, a number of observational studies of **CT-P13** in clinical practice in both ... and the evidence for **efficacy** and **safety** of **biosimilars** in **patients** with **IBD**, the European ...

Introduction · Materials and methods · Results · Crohn's disease patient group

Infliximab Biosimilar (Remsima TM) in Therapy of Inflammatory Bowel ...

<https://www.karger.com/Article/Pdf/453343>  翻译此页

Seventy-four **IBD patients** were **switched** to **biosimilar** IFX and 119 naïve **patients** ... Background: The evidence on the **efficacy** and **safety** of bio- similar **infliximab**

Switching from reference infliximab to CT-P13 in patients with ... - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed/29893581>  翻译此页

作者 : VMF Guerra - 2018

[全部](#)[新闻](#)[图片](#)[购物](#)[地图](#)[更多](#)[设置](#)[工具](#)

找到约 15,800 条结果 (用时 1.30 秒)

P519 Switching from reference infliximab to CT-P13 in ... - ECCO IBD

<https://www.ecco-ibd.eu/.../p519-switching-from-reference-infliximab-to-ct-...> - 翻译此页

However, with the advent of biosimilar treatment such as CT-P13 promises to ... Here, we assess the effectiveness and safety of switching to CT-P13 from infliximab reference product (RP) in patients with IBD. ... All patients were switched from infliximab RP (Remicade®) to CT-P13 ... Loss of efficacy at 12 months was 15.7%.

缺少字词: original

AB0709 Switching from originator infliximab to biosimilar infliximab ...

https://ard.bmj.com/content/77/Suppl_2/1494.3 - 翻译此页

作者: V Venerito - 2018

One out of 2 patients who discontinued CT-P13 IFX had previously ... BD patients from originator IFX to CT-P13 seems to be effective and safe; only a small ... (2017) Rapid loss of efficacy of biosimilar infliximab in three patients with Behcet's disease after ... PTU-073 In Patients with IBD Switching from Originator Infliximab ...

Switching from reference infliximab to CT-P13 in patients wi ...

https://journals.lww.com/.../Switching_from_reference_infliximab_to_CT_P... - 翻译此页

作者: F Argüelles-Arias - 2017 - 被引用次数: 15 - 相关文章

Original Articles: Inflammatory Bowel Disease ... Conclusion Switching from infliximab RP to CT-P13 is efficacious and well tolerated in ... In patients with IBD, a number of observational studies of CT-P13 in clinical practice in both ... and the evidence for efficacy and safety of biosimilars in patients with IBD, the European ...

Introduction · Materials and methods · Results · Crohn's disease patient group

Switching from reference infliximab to CT-P13 in patients with ... - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed/29893581> - 翻译此页

作者: VMF Guerra - 2018

Switching from reference infliximab to CT-P13 in patients with inflammatory ... infliximab has changed

advent of biosimilar treatments such as